RT Journal Article
T1 Oxaliplatin-Biomimetic Magnetic Nanoparticle Assemblies for Colon Cancer-Targeted Chemotherapy: An In Vitro Study.
A1 Jabalera, Ylenia
A1 Garcia-Pinel, Beatriz
A1 Ortiz, Raul
A1 Iglesias, Guillermo
A1 Cabeza, Laura
A1 Prados, Jose
A1 Jimenez-Lopez, Concepcion
A1 Melguizo, Consolacion
K1 MamC
K1 colon carcinoma
K1 magnetite nanoparticles
K1 magnetotactic bacteria
K1 nanocarriers
K1 oxaliplatin
AB Conventional chemotherapy against colorectal cancer (CRC), the third most common cancer in the world, includes oxaliplatin (Oxa) which induces serious unwanted side effects that limit the efficiency of treatment. Therefore, alternative therapeutic approaches are urgently required. In this work, biomimetic magnetic nanoparticles (BMNPs) mediated by MamC were coupled to Oxa to evaluate the potential of the Oxa-BMNP nanoassembly for directed local delivery of the drug as a proof of concept for the future development of targeted chemotherapy against CRC. Electrostatic interactions between Oxa and BMNPs trigger the formation of the nanoassembly and keep it stable at physiological pH. When the BMNPs become neutral at acidic pH values, the Oxa is released, and such a release is greatly potentiated by hyperthermia. The coupling of the drug with the BMNPs improves its toxicity to even higher levels than the soluble drug, probably because of the fast internalization of the nanoassembly by tumor cells through endocytosis. In addition, the BMNPs are cytocompatible and non-hemolytic, providing positive feedback as a proof of concept for the nanoassembly. Our study clearly demonstrates the applicability of Oxa-BMNP in colon cancer and offers a promising nanoassembly for targeted chemotherapy against this type of tumor.
PB MDPI AG
SN 1999-4923
YR 2019
FD 2019-08-01
LK http://hdl.handle.net/10668/14375
UL http://hdl.handle.net/10668/14375
LA en
NO Jabalera Y, Garcia-Pinel B, Ortiz R, Iglesias G, Cabeza L, Prados J, et al. Oxaliplatin-Biomimetic Magnetic Nanoparticle Assemblies for Colon Cancer-Targeted Chemotherapy: An In Vitro Study. Pharmaceutics. 2019 Aug 6;11(8):395.
NO C.J.-L wants to thank projects CGL2016-76723 from the Ministerio de Economía y Competitividad from Spain and Fondo Europeo de Desarrollo Regional (FEDER) for financial support and the Unidad Científica de Excelencia UCE-PP2016-05 of the University of Granada. This work was also supported by the Consejería de Salud de la Junta de Andalucía (projects PI-0476-2016 and PI-0102-2017). Y.J. and B.G.-P. acknowledge FPU2016 grants (FPU16_04580 and FPU16_01716, respectively) from the Ministerio de Educación, Ciencia, y Deporte y Competitividad (Spain).
DS RISalud
RD Apr 5, 2025